INTRODUCTION

Background and rationale
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. According to the worldwide data, the prevalence of PD is 428/100,000 in people aged 60 to 69, 1087/100,000 in people aged 70 to 79, and 1903/100,000 in people over 80. 1 Although medical treatment remains the most effective management of PD, patients will eventually develop motor complications, including motor fluctuation and dyskinesia. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been showed to improve motor symptoms and motor complications better than best medical therapy in advanced PD. [2] [3] [4] However, there is currently no consensus on the optimal timing for performing DBS within the duration of the disease. Recommendations coming from experts in the field support the use of DBS when medications fail to adequately control symptoms or cause severe side effects, because potentially serious risks are associated with surgery and neurostimulation. 5 More recently, with the aim at improving quality of life of patients earlier within the course of the disease, DBS indication has been considered earlier. 6 In 2007, a French pilot study showed that STN DBS is more effective than medications in earlier stage of PD (disease duration of 6.8±1.0 years). 7 In 2013, results from a large-scale trial (the EARLYSTIM study) showed superiority of STN DBS in treating PD patients with early motor complications compared to best medical therapy, regarding quality of life, motor function, and motor complications at 2-year follow-up. 8 A recent retrospective study reported that early-stimulated patients might have better long-term outcome in activities of daily living during "OFF-condition" (assessed by Unified Parkinson's Disease Rating Scale Part II) than the late-stimulated patients. 9 Given these findings, it might be better for PD patients to have DBS surgery earlier, although some non-idiopathic PD patients might be included and the benefit-to-risk ratio could possibly be lower in patients undergoing STN DBS just after the onset of motor complications. 10 To our knowledge, there is currently no ongoing study examining the differences in long-term efficacy and safety between early-and late-stimulated PD patients.
Furthermore, the effects of STN DBS on the dopaminergic system are still not clear. Early radionuclide imaging studies showed that, biomarkers of the dopaminergic terminals in advanced PD patients continued to decrease after DBS surgery, either with dopamine transporter (DAT) single photon emission computed tomography (SPECT) or with 18 F-fluorodopa (F-dopa) positron emission tomography (PET). 11, 12 But functional changes in early-stimulated PD patients are barely studied.
So in this trial, we are going to find out a better timing for STN DBS and assess the postoperative changes of the dopaminergic terminals in both early-and late-stimulated PD patients, with PET imaging of vesicular monoamine transporter 2 (VMAT2), a biomarker that is thought to be less affected by compensation and pharmacological regulation than F-dopa or DAT.
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Objectives
The Early versus Late Application of Subthalamic deep brain Stimulation (ELASS) study is designed to investigate the effects of STN DBS in different stages of PD. It was started in 2013 and is anticipated to be completed in 2020. The primary objective of this study is to compare the therapeutic efficacy and safety of bilateral STN DBS between PD patients with early and late motor complications at four years. The secondary objective of the study is to investigate the changes of dopaminergic terminals by monitoring the integrity of dopaminergic neurons before and four years after DBS with PET imaging of VMAT2.
METHODS AND ANALYSIS
Study design and setting
The ELASS study is a Chinese, multicenter, prospective, open-label, interventional study. Patients are recruited by three centers in China, including (1) the First Affiliated Hospital of Sun Yat-Sen University (affiliation of the principal investigator), Guangzhou, (2) the Prince of Wales Hospital, Hong Kong, and (3) the Shenzhen Second People's Hospital, Shenzhen. Since it's difficult to carry out random allocation in our case, the subjects are allocated to each group simply according to the duration of their motor complications at the time of recruitment. Those with motor complications of three years or less are assigned to the early-stimulation group and the others the late-stimulation group. 
Exclusion Criteria
Patients with one of the following conditions will be excluded: (1) presence of severe metabolic diseases; (2) severe cardiac/respiratory/renal/hepatic diseases; (3) secondary parkinsonism or multiple system atrophy; (4) illiteracy or insufficient language skills to complete the questionnaires; (5) poor compliance or unrealistic expectations; (6) women who are pregnant or breast feeding; (7) simultaneous participation in another clinical trial.
Procedures
Baseline assessment PD patients with an intention of receiving DBS are screened and recruited by neurologists in the outpatient clinic. After recruitment, there is at least a month for observation and preparation. During this period, drug regimens remain unchanged and patients complete the Parkinson's Disease Home Diary 15 on three consecutive days in each of two consecutive weeks. Then they are admitted to the neurology department for preoperative evaluation, including (1) motor function in both "off" and "on" states, accessed by MDS-UPDRS Part III, (2) dyskinesia, accessed by the Unified Dyskinesia Rating Scale (UDysRS), 16 are included and transferred to the neurosurgery department for implantation of DBS device, and those who don't are excluded from the study. Follow-ups are scheduled for one year and four years after surgery.
Motor symptoms are assessed in two conditions (off-and on-medication) preoperatively and in four conditions (off-medication/on-stimulation, off-medication/off-stimulation, on-medication/off-stimulation, and on-medication/ on-stimulation, consecutively) postoperatively. The off-medication state is defined as the motor function after withdrawal of anti-parkinsonian medications for at least 12 hours. The on-medication state refers to the condition when medications take full effect. 150% of the usual morning 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y dose is used in the preoperative levodopa challenge test and the same dose is used in each follow-up. Medications are converted into an equivalent dose of immediate-released levodopa (Madopar) for administration, according to the following formula 25 : 100 mg immediate-released levodopa = 133 mg controlled-released levodopa = 1 mg pramipexole = 100 mg piribedil = 10 mg selegiline; each dose of levodopa was 25% more effective with entacapone. The off-/on-stimulation state is assessed at least half an hour after switching off/on the device.
PET imaging
Patients recruited by the First Affiliated Hospital of Sun Yat-Sen University, which is the only center equipped with PET/CT scanner, will undergo PET imaging preoperatively and four years after surgery. 
Sample size
Since it is easier to recruit patients with motor complications of more than three years, we decided that N2, the size of the late-stimulation group, should be twice N1, the size of the early-stimulation group. Calculation of the sample size is based on the primary outcome of quality of life measured by PDQ-39.
According to a retrospective analysis of our previous data, we expected a mean difference of 20% in the improvement of PDQ-39 summary index (PDQ-39 SI) between the groups at endpoint and considered it to be clinically meaningful. With a two-sided significance level of 5% and statistical power at 80% and allowing for a 20% dropout rate, a sample size of 200 patients is needed to test the hypothesis with the non-parametric 2-sided Manne-Whitney test, including 67 for the EARLY Group and 133 for the LATE Group.
Outcomes
Primary outcomes are as follows: 
Data collection methods
All data collected from each patient are documented in a paper case report form (CRF) and sent to the PI center every half a year. Before the start of the study, researchers from each center were trained to collect and put down the data correctly. Contents of the CRFs are audited by three monitors before being entered into the database. Personal data are made anonymous and codified. All adverse events are collected in the 'adverse event' section of the CRF, including the date of occurrence, duration, management and outcome.
Statistical methods
Summaries of continuous variables are presented as means (±SD) for normally distributed data and as medians with interquartile ranges for skewed data; categorical variables are presented as frequencies (percentages). Continuous variables were compared with the use of Student's t-test or the Mann-Whitney test (for nonnormally distributed data), and categorical data with the use of chi-square tests. The statistical analyses were performed with the use of SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). All statistical tests were two-tailed, and a P value of less than 0.05 was considered to indicate statistical significance.
ETHICS AND DISSEMINATION
The study was approved by the Medical Ethical Committee of the First Affiliated Hospital, Sun Yat-sen University, on 28 February 2013, and was registered on the ClinicalTrial.gov (number: NCT01922388). Any amendment will be submitted to the local Ethics Committee. Signed informed consent is required of each patient enrolled. We will disseminate the results of our study via presentations at international conferences and publications in peer reviewed journals.
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Methods and analysis:
The study is a multicenter, prospective, observational research, with an expected enrollment of 200 PD patients who will be followed up for four years. PD patients who met the criteria for STN DBS surgery will be allocated to the early-or late-stimulation group according to the duration of their motor complications. The primary outcome is changes in quality of life measured by the 39-item Parkinson's Disease Questionnaire summary index (PDQ-39 SI) from baseline to four years. The secondary outcomes are changes in motor function measured by MDS-revised Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, self-reported experiences of daily living measured by MDS-UPDRS Part I B and Part II, and good "on" time measured by the patient diary.
Ethics and dissemination:
The study received ethical approval from the Medical Ethical Committee of the First Affiliated Hospital, Sun Yat-sen University. The results of this study will be published in peer-reviewed journals and presented at international conferences.
Trial registration number: NCT01922388
Strengths and limitations of this study
The study is a multicenter research with sufficient sample size and long-term follow-up.
The study would provide evidence for neurologists in strategy selection when treating PD patients.
The study is observational.
There is still a risk of recruiting non-idiopathic PD patients despite our strict inclusion criteria.
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Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. According to the worldwide data, the prevalence of PD is 428/100,000 in people aged 60 to 69, 1087/100,000 in people aged 70 to 79, and 1903/100,000 in people over 80. 1 Although medical treatment remains the most effective management of PD, patients will eventually develop motor complications, including motor fluctuation and dyskinesia. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been showed to improve motor symptoms and motor complications better than best medical therapy in advanced PD. [2] [3] [4] However, there is currently no consensus on the optimal timing for performing DBS within the duration of the disease. Recommendations coming from experts in this field support the use of DBS when medications fail to adequately control symptoms or cause severe side effects, because potentially serious risks are associated with surgery and neurostimulation. 5 More recently, with the aim at improving quality of life of patients earlier within the course of the disease, DBS indication has been 6 In 2007, a French pilot study showed that STN DBS is more effective than medications in earlier stage of PD (disease duration of 6.8±1.0 years). 7 In 2013, results from a large-scale trial (the EARLYSTIM study) showed superiority of STN DBS in treating PD patients with early motor complications compared to best medical therapy, regarding quality of life, motor function, and motor complications at 2-year follow-up. 8 A recent retrospective study reported that early-stimulated patients might have better long-term outcome in activities of daily living during "OFF-condition" (assessed by Unified Parkinson's Disease Rating Scale Part II) than the late-stimulated patients. 9 Given these findings, it might be better for PD patients to have DBS surgery earlier, although some non-idiopathic PD patients might be included and the benefit-to-risk ratio could possibly be lower in patients undergoing STN DBS just after the onset of motor complications. 10 To our knowledge, there is currently no ongoing study examining the differences in long-term efficacy and safety between early-and late-stimulated PD patients.
Objectives
The Early versus Late Application of Subthalamic deep brain Stimulation (ELASS) study was started in 2013 and is anticipated to be completed in 2020. The primary objective of this study is to demonstrate statistically significant difference in quality of life (PDQ-39 SI) improvement between PD patients with early and late motor complications from baseline to four years after DBS surgery. Additional objectives are to summarize or characterize the following: changes in motor function (MDS-UPDRS III) from baseline (off medication) to four years (off medication/on stimulation); changes in self-reported experiences of daily living (MDS-UPDRS Part I B and Part II) from baseline to four years; changes in good "on" time (patient diary) from baseline to four years; changes in cognition, emotion and non-motor symptoms from baseline to four years; safety profile of both groups based on severe adverse effects reported throughout the study.
METHODS AND ANALYSIS
Study design and setting
The ELASS study is a Chinese, multicenter, prospective, observational study. Patients are recruited by three centers in China, including (1) the First Affiliated Hospital of Sun Yat-Sen University (affiliation of the principal investigator), Guangzhou, (2) the Prince of Wales Hospital, Hong Kong, and (3) the Shenzhen Second People's Hospital, Shenzhen. The subjects are allocated to each group according to the duration of their motor complications at the time of recruitment. Those with motor complications of three years or less are assigned to the early-stimulation group 8 and the others the late-stimulation group.
Eligibility criteria
Inclusion criteria
Patients will be eligible for recruitment if they meet the following criteria: (1) a diagnosis of idiopathic Parkinson's disease according to British brain bank criteria; (2) disease duration ≥ four years; (3) good response to levodopa, i.e. more than 30% improvement [11] [12] [13] in motor function after an acute levodopa 24 and (8) brain MRI. Those who meet the inclusion criteria are included and transferred to the neurosurgery department for implantation of DBS device, and those who don't are excluded from the study. Follow-ups are scheduled for one year and four years after surgery.
Motor symptoms are assessed in two conditions (off-and on-medication) preoperatively and in four conditions (off-medication/on-stimulation, off-medication/off-stimulation, on-medication/off-stimulation, and on-medication/ on-stimulation, consecutively) postoperatively. The off-medication state is defined as the motor function after withdrawal of anti-parkinsonian medications for at least 12 hours. The on-medication state refers to the condition when medications take full effect. 150% of the usual morning dose is used in the preoperative levodopa challenge test and the same dose is used in each follow-up. Medications are converted into an equivalent dose of immediate-released levodopa (Madopar) for administration, according to the following formula 25 : 100 mg immediate-released levodopa = 133 mg controlled-released levodopa = 1 mg pramipexole = 100 mg piribedil = 10 mg selegiline; each dose of levodopa was 25% more effective with entacapone. The off-/on-stimulation state is assessed at least half an hour after switching off/on the device.
Surgery
All centers are experienced in DBS surgery, with surgeons performing the surgery for more than 5 years at Stimulation parameters programming A month after surgery, patients come to the clinic in the "off" state for initial programming of electrical parameters of stimulation. The IPG is turned on and all the contacts are tested according to a standard protocol. With the IPG as anode, the tested contact as cathode, pulse width of 60 μs and frequency of 130 Hz, the amplitude is gradually increased to 5-6 V in increments of 0.5-1 V or until intolerable side effects exists. Tremor and rigidity of the tested limbs are scored and all the adverse effects, if any, are recorded each time the amplitude is increased. The electrode contacts with the lowest threshold for inducing a benefit and the highest threshold for side effects are selected for chronic stimulation. Initial stimulation parameters are usually set at 60 μs and 130 Hz, with variable voltages (usually 1.0-2.0 V). If the result is not satisfactory by voltage adjustments only, further modification of parameters can include changes of pulse widths, frequencies or configurations. In the subsequent programming sections, parameters and medications are progressively adjusted to achieve maximum improvement.
Sample size
Since it is easier to recruit patients with motor complications of more than three years, we decide that n B , the size of the late-stimulation group, should be twice n A , the size of the early-stimulation group. Calculation of the sample size is based on the primary outcome of quality of life measured by PDQ-39 summary index (PDQ-39 SI). According to a retrospective analysis of our previous data, the adjusted mean improvement of PDQ-39 SI from baseline to 3 years after DBS surgery is 16 2. Changes in good "on" time, including "on" without dyskinesia and "on" with non-troublesome dyskinesia based on Parkinson's disease home diary, from baseline to endpoint.
3. Changes in MDS-UPDRS patient questionnaire (Part I B and Part II) scores from baseline to endpoint.
4. Changes in cognition, emotion and non-motor symptoms measured by MOCA, MMSE, HAMA, HAMD, BDI and NMSS, from baseline to endpoint.
5. Safety profile of both groups based on severe adverse effects reported through four years.
Data collection methods
Assessment of safety: In this study, safety data will be inclusive of all adverse effects (AEs), from the point of subject enrollment to the final follow-up visit or discontinuation, whichever comes first. Reports of AEs will include the following information at minimum: date of event; diagnosis or description of the event; assessment of the seriousness; treatment; outcome and date.
Collection of data: Before the start of the study, investigators from each center were trained to record the data correctly. Data collected from each patient are put down in a paper case report form (CRF) and sent to the PI center every half a year. A copy of CRF is placed in the subject's binder at the investigation site. Contents of the CRFs are audited by three monitors before being entered into the database. Personal data are made anonymous and codified.
Statistical methods
The parameters of interest are mean changes of the observed values from baseline to 4-year follow-up. Our hypothesis is that the average change of PDQ-39 SI in the early group (μ A ) is statistically different from that of the late group (μ B ): H 0 : μ A −μ B =0, H 1 : μ A −μ B ≠0. The primary analysis will be a complete case analysis (i.e. using only cases with complete data), supported by sensitivity analysis, where missing data will be filled in using the multiple imputation method. The number, timing, pattern and reason for missing data or dropout will be reported, as well as their possible implications in efficacy and safety assessments. Statistical analysis of the primary and secondary endpoints will be performed within the framework of the Generalized Linear Model with baseline adjustment. Main effects (group and time), effects of covariates (age, center), group-by-time interaction, and group-by-covariate interaction will be calculated and analyzed using analysis of covariance (ANCOVA). Summaries of continuous variables will be presented as means (±SD) for normally distributed data and as medians with interquartile ranges for skewed data; categorical variables will be presented as frequencies (percentages). Statistical analysis will be performed using the SPSS 13.0. All statistical tests will be two-tailed, and a P value of less than 0.05 is considered to indicate statistical significance. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
ETHICS AND DISSEMINATION
Methods and analysis:
200 PD patients will be enrolled in this multicenter, prospective and observational study, and will be followed up for four years. PD patients who meet the criteria for STN DBS surgery will be allocated to either the early-or late-stimulation group based on the duration of their motor complications.
The primary outcome will be changes in quality of life from baseline to four years, measured using the 39-item Parkinson's Disease Questionnaire summary index (PDQ-39 SI). The secondary outcomes include changes in motor function measured using MDS-revised Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, self-reported experiences of daily living measured using MDS-UPDRS Part I B and Part II, good "on" time recorded by the patients using a diary and safety profile of both groups.
Ethics and dissemination:
Trial registration number: NCT01922388
Strengths and limitations of this study
The study is a multicenter research study with sufficient sample size and long-term follow-up duration.
The study will provide evidence for neurologists in strategy selection when treating PD patients.
There is a risk of recruiting non-idiopathic PD patients despite our strict inclusion criteria.
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. Based on worldwide data, the prevalence of PD is 428/100,000 in people aged between 60 and 69, 1087/100,000 in people aged between 70 and 79, and 1903/100,000 in people over the age of 80. 1 Although oral medical treatment remains the most effective for the management of PD, patients will eventually develop motor complications, including motor fluctuation and dyskinesia. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been demonstrated to improve motor symptoms and complications better than the most effective oral medications approved for advanced PD . [2] [3] [4] However, there is currently no consensus on the optimal timing for performing DBS during the course of the disease.
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Recommendations from experts in this field support the use of DBS only when medications fail to adequately control symptoms or cause severe side effects, because of the potentially serious risks that are associated with surgery and neurostimulation. 5 However, more recently, DBS have been considered earlier for therapeutic intervention with the aim of improving the quality of life in patients during the course of the disease. 6 In 2007, a French pilot study showed that STN DBS was more effective than oral medications for early stages of PD (disease duration of 6.8±1.0 years). 7 In 2013, results from a large-scale trial (the EARLYSTIM study) showed superiority of STN DBS for treating PD patients with early motor complications compared to the best oral medications available. This was evaluated based on quality of life, motor function, and motor complications during a 2-year follow-up study. 8 A recent retrospective study reported that early-stimulated patients might have better long-term outcome in the activities of daily living during "OFF-condition" (assessed by Unified Parkinson's Disease Rating Scale Part II) than with late-stimulated patients. 9 Given these findings, it might be better for PD patients to have DBS surgery earlier. While there may be risks that non-idiopathic PD patients might be included, the benefit-to-risk ratio could possibly be lower for patients undergoing STN DBS just after the onset of motor complications. 10 To our knowledge, there is currently no ongoing study examining the differences in long-term efficacy and safety between early-and late-STN DBS stimulated PD patients.
Objectives
Early versus Late Application of Subthalamic deep brain Stimulation (ELASS) study was initiated in 2013, and is anticipated to be concluded by 2020. The primary objective of this study is to demonstrate statistically significant difference in quality of life (PDQ-39 SI) and improvement in PD patients with early and late motor complications measured from baseline to four years after DBS surgery. Additional objectives are to summarize or characterize the following: changes in motor function (MDS-UPDRS III) from baseline (off medication) to four years (off medication/on stimulation); changes in self-reported experiences of daily living (MDS-UPDRS Part I B and Part II) from baseline to four years; changes in good "on" time (using a patient diary) from baseline to four years; changes in cognition, emotion and non-motor symptoms from baseline to four years and safety profiles for both groups based on severe adverse effects reported throughout the study. 
METHODS AND ANALYSIS
Study design and setting
Eligibility criteria
Patients will be eligible for recruitment if they meet the following criteria: (1) a diagnosis of idiopathic Parkinson's disease based on the British brain bank criteria; (2) disease duration ≥ four years; (3) good response to levodopa, i.e. more than 30% improvement [11] [12] [13] 
Exclusion Criteria
Procedures
Baseline assessment PD patients with an intention of receiving DBS will be screened and recruited by neurologists in an outpatient clinic. When a patient decides to participate in the study, the Informed Consent Form (ICF) will be signed and personally dated by the patient or legally authorized representative and the investigator. One copy of the signed ICF will be sent to the PI's institute and one will be kept in the patient's binder at the investigation site. After recruitment, there will be at least a month for observation and preparation. During this period, drug regimens will remain unchanged and patients will have to complete the Parkinson's Disease Home Diary 15 for three consecutive days for a period of two consecutive weeks. They will then be admitted to the neurology department for preoperative evaluation, which includes (1) motor function in both "off" and "on" states, accessed using MDS-UPDRS Part III, (2) dyskinesia, accessed using Unified Dyskinesia Rating Scale (UDysRS), 16 (3) quality of life, accessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39), 17 (4) sleep, accessed using the Parkinson's Disease Sleep Scale-Chinese version (PDSS-CV) 18 and the Pittsburgh Sleep Quality Index (PSQI), 19 (5) emotion, accessed using the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale (HAMD) 20 and the Beck Depression
Inventory (BDI), 21 (6) cognition, accessed using the Mini-Mental State Examination (MMSE) 22 and the Montreal Cognitive Assessment (MoCA), 23 (7) non-motor symptoms, accessed using the Non-Motor 24 and (8) brain MRI. Those who meet the inclusion criteria will be transferred to the neurosurgery department for implantation of the DBS device. Patients who fail the inclusion criteria will be excluded from the study. Follow-ups will be scheduled for one year and four years after surgery.
Motor symptoms will be assessed using two conditions (off-and on-medication) preoperatively, and in four conditions (off-medication / on-stimulation, off-medication / off-stimulation, on-medication / off-stimulation, and on-medication / on-stimulation, consecutively) postoperatively. The off-medication state is defined as the motor function after withdrawal of anti-parkinsonian medications for at least 12 hours. The on-medication state refers to the condition when medications take their full effect. 150% of the normal morning dose will be used for the preoperative levodopa challenge test and the same dose will be used for each follow-up. Medications will be converted into an equivalent dose of immediate-released levodopa (Madopar) for administration, based on the following formula 25 : 100 mg immediate-released levodopa = 133 mg controlled-released levodopa = 1 mg pramipexole = 100 mg piribedil = 10 mg selegiline; each dose of levodopa is 25% more effective with entacapone. The off-/on-stimulation state will be assessed at least half an hour after switching off/on the device.
Surgery
All centers have the expertise to perform DBS surgery, with surgeons having more than 5 years of experience at the start of the trial. Surgical procedures between each center may differ, but the following requirements will be met to guarantee an optimal approach: (1) Targeting and trajectory planning will be based on the fusion of non-stereotactic MRI scans with stereotactic CT scans. (2) Electrode implantation can be done under either local or general anesthesia, but microelectrode recordings (MER) will be mandatory for all patients. During the MER in the STN, passive movement of the contralateral limbs will be performed to observe whether there are any movement-related neuronal firing changes. In cases where general anesthesia is used, somatosensory evoked potentials (SSEPs) elicited by median nerve stimulation (MNS) will be used to facilitate localization of the STN. 26 Test stimulations will be applied to patients under local anesthesia to monitor improvements of parkinsonian signs and stimulation-induced side effects. (3) Leads will be secured at the burr-hole site using the stimloc system (Stimloc, Medtronic , US) will be implanted subcutaneously usually at the right sub-clavicular area, with in the same procedure for the electrodes.
Stimulation parameter programming A month after surgery, patients will visit the clinic in the "off" state for initial programming of electrical parameters for stimulation. The IPG will be turned on and all the contacts tested based on a standard protocol. With the IPG as anode, the tested contact as cathode, pulse width of 60 μs and frequency of 130 Hz, the amplitude will be gradually increased to 5-6 V in increments of 0.5-1 V or until side effects are intolerable. Tremor and rigidity of the tested limbs will be scored and all adverse effects, if any, will be recorded each time the amplitude is increased. The electrode contacts with the lowest threshold for inducing a benefit and the highest threshold for side effects will be selected for chronic stimulation. Initial stimulation parameters will be set at 60 μs and 130 Hz, with variable voltages (usually 1.0-2.0 V). If results are not satisfactory by voltage adjustments only, further modification to parameters will include pulse width, frequencies or configurations. Subsequent programming sections to the parameters and medications will be progressively adjusted to achieve maximum improvement.
Sample size
Given that it is easier to recruit patients with motor complications of more than three years, we decide that n B , the size of the late-stimulation group, should be twice n A , the size of the early-stimulation group. Calculation of the sample size will be based on the primary outcome of quality of life measured using PDQ-39 summary index (PDQ-39 SI). Based on retrospective analysis of our previous data, the adjusted mean improvement of PDQ-39 SI from baseline to 3 years after DBS surgery was 16 
Outcome measurements
Primary outcome: Changes in quality of life measured using PDQ-39 SI from baseline to endpoint.
Secondary Outcomes will be measured based on;
1. Changes in motor function measured using MDS-UPDRS Part III scores from baseline to endpoint.
2. Changes in good "on" time, including "on" without dyskinesia and "on" with non-troublesome dyskinesia based on Parkinson's disease home diary, from baseline to endpoint.
4. Safety profile of both groups based on severe adverse effects reported through four-year study duration.
Data collection methods
Assessment of safety: Safety data will be inclusive of all adverse effects (AEs), from the point of subject enrollment to the final follow-up visit or discontinuation, whichever comes first. Reports of AEs will minimally include the following information; date of event; diagnosis or description of the event; assessment of the seriousness; treatment; outcome and date.
Collection of data: Before the start of the study, investigators from each center will be trained on proper data recording. Data collected from each patient will be transcribed in a paper case report form (CRF) and sent to the PI's center every half a year. A copy of the CRF will be placed in the subject's binder at the investigation site. Three monitors will audit the contents of the CRF before being entered into the database. Personal data will be coded and made anonymous. 
Statistical methods
The parameters of interest will be mean changes of the observed values from baseline to 4-year follow-up. Our hypothesis is that the average change of PDQ-39 SI in the early group (μ A ) will be statistically different from that of the late group (μ B ): H 0 : μ A −μ B =0, H 1 : μ A −μ B ≠0. The primary analysis will be a complete case analysis (i.e. using only cases with complete data), supported by sensitivity analysis, where missing data will be filled in using the multiple imputation method. The number, timing, pattern and reason for missing data or dropout will be reported, as well as their possible implications in efficacy and safety assessments. Statistical analysis of the primary and secondary endpoints will be performed within the framework of the Generalized Linear Model with baseline adjustment. Covariates including age, disease duration, baseline motor scores, and baseline PDQ-39 SI scores will be introduced into the linear model. Main effects (group and time), effects of covariates, group-by-time interaction, and group-by-covariate interaction will be calculated and analyzed using analysis of covariance (ANCOVA). Summaries of continuous variables will be presented as means (±SD) for normally distributed data and as medians with interquartile ranges for skewed data; categorical variables will be presented as frequencies (percentages). Statistical analysis will be performed using the SPSS 13.0. All statistical tests will be two-tailed, and a P value of less than 0.05 is considered to indicate statistical significance.
ETHICS AND DISSEMINATION
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